Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07118202 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma

Study acronym: TARGET-HCC
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Aug 31, 2027 to Aug 31, 2028
    • Eligibility criteria expanded, about 71 words
    • Site contacts updated at 4 of 6 sites
    v4
  2. Study sites: 1 to 6v3
  3. Start date changed from estimate of Aug 31, 2025 to Oct 20, 2025v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect overall survival in advance HCC * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device
Trial Details
NCT Number NCT07118202
Lead Sponsor Barbara Ann Karmanos Cancer Institute
Collaborators: THERABIONIC INC.
Conditions
(from sponsor)		 Hepatocellular Carcinoma Recurrent
Enrollment 198 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov